APA (7th ed.) Citation

Y, C., MK, T., N, E. H., N, N., A, J., M, G., . . . R, B. (2021). ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Molecular cancer, 20(1), 12. https://doi.org/10.1186/s12943-020-01306-2

Chicago Style (17th ed.) Citation

Y, Cheli, et al. "ITGBL1 Is a New Immunomodulator That Favors Development of Melanoma Tumors by Inhibiting Natural Killer Cells Cytotoxicity." Molecular Cancer 20, no. 1 (2021): 12. https://doi.org/10.1186/s12943-020-01306-2.

MLA (9th ed.) Citation

Y, Cheli, et al. "ITGBL1 Is a New Immunomodulator That Favors Development of Melanoma Tumors by Inhibiting Natural Killer Cells Cytotoxicity." Molecular Cancer, vol. 20, no. 1, 2021, p. 12, https://doi.org/10.1186/s12943-020-01306-2.